Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095890 | 0.91 | CCKBR (0.50) | CCKBRCYP2D6CYP2C9 | |
| SCHEMBL6094324 | 0.83 | CCKBR (0.57) | CCKBRKMO | |
| SCHEMBL6096491 | 0.81 | CCKBR (0.57) | CCKBRPDE4D | |
| SCHEMBL6096460 | 0.81 | CCKBR (0.56) | CCKBR | |
| SCHEMBL6334200 | 0.78 | CCKBR (0.60) | CCKBRKMO | |
| SCHEMBL6339248 | 0.77 | CCKBR (0.61) | CCKBRCYP2C9CYP3A4CYP2C19 | |
| SCHEMBL6334684 | 0.77 | CCKBR (0.61) | CCKBRPDE4DKMO | |
| SCHEMBL6334704 | 0.77 | CCKBR (0.61) | CCKBR | |
| SCHEMBL6338529 | 0.77 | CCKBR (0.59) | CCKBRKMO | |
| SCHEMBL6334315 | 0.76 | CCKBR (0.60) | CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034048-B2 | Gastrin and cholecystokinin receptor ligands (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2006-04-25 | — | — | US | disclosed |
| US-20030191116-A1 | Gastrin and cholecystokinin receptor ligands (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-09 | — | — | US | disclosed |
| WO-2001085724-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191116-A1 | Gastrin and cholecystokinin receptor ligands (III) | CCKAR, CCKBR, GRPR | CCKBR 2/4885PDE4A 4215/4885PDE4B 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.